Leerink Partners Raises Q2 Earnings Forecast for Medpace Holdings

Leerink Partners, a renowned financial firm, has revised its Q2 2025 earnings projections for Medpace Holdings, Inc. (NASDAQ: MEDP). According to M. Cherny, an expert at Leerink Partners, the new estimate suggests that Medpace will report earnings of $2.93 per share for the quarter, reflecting an upward revision from previous forecasts.

In recent Medpace developments, Director Fred B. Davenport, Jr. executed a notable sale of 1,712 shares of Medpace stock on Thursday, April 24th, signaling potential strategic shifts within the company.

Furthermore, Orion Portfolio Solutions LLC significantly increased its holdings in Medpace shares by 347.6% during the fourth quarter, underlining growing investor confidence in the company’s potential.

Medpace Holdings, Inc.: Driving Outsourced Medical Innovation

Medpace Holdings, Inc. operates as a leading provider of outsourced medical development services catering to the biotechnology, healthcare, and pharmaceutical industries.

For more detailed insights and daily updates on Medpace and its market performance, subscribe to MarketBeat.com’s free newsletter for comprehensive news and expert analysis.

Kingsman | Financial Advisor

Kingsman a 35-year-old financial advisor from London, UK, epitomizes the blend of analytical prowess and personable guidance. With a decade of experience in the financial sector, Kingsman has cultivated a reputation for his strategic approach to wealth management and investment advising. His journey began at the University of Oxford, where he graduated with honours in Economics, a discipline that fueled his fascination with the financial markets and their intricacies.

See Full Bio